Leqvio Manufacturer Bridge Programs: How to Get Inclisiran Cheaper in 2026

What Is Leqvio and Why Does Cost Matter?

Leqvio (inclisiran) is a small interfering RNA (siRNA) therapy that silences PCSK9 messenger RNA in the liver, cutting LDL-C production at the genetic level rather than blocking the PCSK9 protein after it is made. The FDA approved inclisiran on December 22, 2021, for adults with primary hyperlipidemia or heterozygous familial hypercholesterolemia (HeFH) as an adjunct to diet and maximally tolerated statin therapy. [1]

Cost is a real barrier. Inclisiran's wholesale acquisition cost sits near $3,250 per injection. Because it is given at 0, 3, and 6 months, then every 6 months after that, a patient's first-year drug cost can exceed $9,700 before insurance adjustments. That price point is consistent with other PCSK9-class agents and reflects the high cost of RNA-based manufacturing.

Clinical Efficacy Establishing Medical Necessity

The ORION-11 trial (N=1,617) demonstrated that inclisiran 284 mg produced a 49.9% time-averaged reduction in LDL-C from baseline versus placebo at day 510, with P<0.001. [2] ORION-10 (N=1,561) reported a 52.3% placebo-corrected LDL-C reduction in patients already on statins. [3] These reductions are clinically meaningful and comparable to those seen with evolocumab and alirocumab, the two approved monoclonal PCSK9 inhibitors. [4]

Why Payers Require Prior Authorization

Because PCSK9 inhibitor therapies carry high list prices, nearly every major insurer requires prior authorization (PA) before dispensing inclisiran. The ACC/AHA 2022 guideline on nonstatin therapies states that PCSK9 inhibitors are recommended for patients with atherosclerotic cardiovascular disease (ASCVD) whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy, or for HeFH patients with LDL-C above 100 mg/dL. [5] Documenting these thresholds in the PA request is the first step before any bridge program applies.

How the Novartis Leqvio Co-pay Assistance Program Works

For commercially insured patients, the Novartis co-pay card is the fastest way to reduce out-of-pocket costs to $0 per dose. Enrollment takes roughly 10 minutes online or by phone through the Novartis One PSP (Patient Support Program).

Eligibility Criteria

To qualify for the co-pay card, a patient must:

• Have a valid commercial insurance plan (employer-sponsored, individual marketplace, or commercial HMO/PPO)
• Have a prescription for Leqvio written by a licensed US prescriber
• Be a US resident and not enrolled in any federal or state government insurance program at the time of application
• Not be receiving the drug through a 340B-covered entity

Patients on Medicare Part B, Medicare Part D, Medicaid, CHIP, TRICARE, or the VA system are explicitly excluded from co-pay card benefits. This exclusion is standard across manufacturer programs and is driven by federal anti-kickback statute regulations. [6]

Benefit Amounts and Duration

Novartis has set the commercial co-pay benefit so that eligible patients pay $0 per injection, with the program covering up to the full out-of-pocket cost after insurance. Specific annual caps are subject to change; the current cap and renewal conditions are posted at the Novartis One PSP portal (novartis.com/leqvio). Because Leqvio is administered in a clinical office, the co-pay assistance check is typically issued to the dispensing specialty pharmacy, not directly to the patient. Most 340B hospitals and certain community health centers are excluded from program participation.

How to Enroll

1. The prescribing cardiologist or lipid specialist submits the PA to the patient's insurer.
2. The Novartis One PSP team (1-888-NOW-NOVA) verifies insurance, confirms co-pay card eligibility, and coordinates specialty pharmacy routing.
3. The specialty pharmacy ships the drug to the office or infusion center where the nurse administers the subcutaneous injection.
4. The co-pay card covers the patient's share at the pharmacy adjudication step.

Patients can also self-enroll at leqvio.com, where a benefits investigation is triggered automatically. [6]

Novartis Patient Assistance Foundation: Free Drug for Uninsured Patients

Uninsured and underinsured patients who cannot afford Leqvio may qualify for free medication through the Novartis Patient Assistance Foundation (NPAF).

Income and Insurance Requirements

NPAF income thresholds are updated annually. As of 2026, the general guideline is a household income at or below 400% of the Federal Poverty Level (FPL), though Novartis retains discretion to approve patients outside this band based on documented financial hardship. Patients must be US residents, lack adequate insurance coverage for Leqvio, and not be eligible for a government program that would otherwise cover the drug. The FDA's Drug Shortages and Patient Assistance page provides background on how manufacturer PAPs interact with federal coverage requirements. [7]

Application Process

Applications are submitted through the NPAF portal or via the prescriber's office. Required documents include:

• Signed prescriber attestation confirming the diagnosis and medical necessity
• Proof of income (most recent tax return or pay stubs for the last three months)
• Proof of insurance status (denial letter, insurance card, or attestation of no coverage)

Processing typically takes 10 to 15 business days. Once approved, drug is shipped free of charge to the dispensing site for the approved enrollment period, usually 12 months with annual renewal.

Medicare Patients: Bridge Programs Do Not Apply, But Other Paths Exist

This is the most common point of confusion. Medicare beneficiaries cannot use the Novartis commercial co-pay card. The anti-kickback statute and the Beneficiary Inducement CMP prohibit manufacturers from subsidizing cost-sharing for Medicare patients. [6]

Medicare Part B Coverage

When a physician or qualified non-physician practitioner administers inclisiran in an office or outpatient hospital setting, it bills under Medicare Part B as a physician-administered drug (J-code). In 2024, the CMS assigned HCPCS code J1815 (pending, verify current J-code with CMS HCPCS database). Part B covers 80% after the Part B deductible; the patient owes 20% coinsurance. A Medigap supplemental policy (Plans C, D, G, F) may cover that 20%. [8]

Medicare Part D and Extra Help

If inclisiran is dispensed through a specialty pharmacy rather than administered in-office, it may fall under Part D. The Low Income Subsidy (LIS), also called Extra Help, can reduce Part D cost-sharing to $1.10 to $10.35 per prescription (2025 benchmark amounts) for qualifying beneficiaries. The Social Security Administration manages Extra Help enrollment at ssa.gov/extrahelp. [8]

State Pharmaceutical Assistance Programs

Some states maintain SPAPs that wrap around Medicare to cover residual cost-sharing. New York's EPIC program and California's PACE program are examples. A social worker or the NPAF navigator can identify applicable state programs for patients in those states.

Can You Use HSA or FSA Funds for Leqvio?

Yes. Inclisiran is a prescription drug used to treat hyperlipidemia, which is a qualified medical expense under IRS Publication 502. [9] Both Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) can pay for the drug and the associated office administration fee. This is true regardless of whether the patient is using a co-pay card for the drug cost itself, the office visit copay, administration fee, or any residual drug cost-sharing can all be paid with HSA/FSA dollars.

For patients whose insurer classifies inclisiran under a high-deductible plan's specialty drug tier, using an HSA to cover the deductible phase can meaningfully reduce net out-of-pocket costs before the co-pay card takes over. The IRS defines HSA-eligible expenses broadly to include prescription medications and medical services ordered by a physician. [9]

How Inclisiran's Dosing Schedule Affects Bridge Program Strategy

Inclisiran's every-6-month dosing schedule (after the initial two loading doses) is clinically and financially unusual. Most specialty drug bridge programs are structured around monthly refills. Leqvio's schedule means that in a calendar year, a new patient receives three injections (month 0, month 3, month 6) and a maintenance patient receives two injections (month 6 and month 12).

Implications for Annual Benefit Caps

If the co-pay card has an annual dollar cap, three doses in year one will exhaust more of that cap than two doses in year two. Patients and prescribers should confirm the cap amount with the Novartis One PSP team before the third dose of year one.

Timing Enrollment Before the First Dose

Because the PA process, specialty pharmacy routing, and co-pay card activation all take time, initiating the benefits investigation 4 to 6 weeks before the planned first injection date prevents gaps. Novartis One PSP can process bridge enrollment in parallel with the insurer's PA review, so patients are not waiting twice.

Comparing Leqvio Access Programs to PCSK9 Monoclonal Antibody Programs

The table below contrasts inclisiran's access programs with those for evolocumab (Repatha, Amgen) and alirocumab (Praluent, Sanofi/Regeneron). This comparison was compiled by the HealthRX Access team based on program terms current as of June 2026 and is not available in this form from any single manufacturer source.

| Feature | Leqvio (inclisiran) | Repatha (evolocumab) | Praluent (alirocumab) | |---|---|---|---| | Commercial co-pay card | Yes, $0 target OOP | Yes, $0 target OOP | Yes, $0 target OOP | | Medicare patients eligible | No | No | No | | Patient assistance (uninsured) | NPAF | Amgen Assist 360 | Sanofi Patient Connection | | Doses per year (maintenance) | 2 | 24 (monthly) or 12 (biweekly) | 24 or 12 | | Administration setting | Office/clinic | Home self-injection | Home self-injection | | HSA/FSA eligible | Yes | Yes | Yes | | 340B exclusion | Yes | Yes | Yes |

The once-daily or biweekly self-injection convenience of monoclonal antibodies matters for some patients, while others prefer the in-office every-6-month model that removes adherence burden. The ORION-3 open-label extension showed that inclisiran maintained a 44.3% LDL-C reduction at 4 years with no new safety signals. [10] Repatha's FOURIER trial (N=27,564) showed evolocumab reduced major cardiovascular events by 15% versus placebo. [4] No head-to-head MACE trial between inclisiran and a monoclonal antibody has been completed as of mid-2026.

What to Do If Your Prior Authorization Is Denied

PA denials for inclisiran are common on the first attempt because many insurer step-therapy requirements mandate two or more documented statin trials first. The American College of Cardiology's PCSK9 inhibitor access document notes that step-therapy barriers are the leading cause of delay in PCSK9 class prescribing. [5]

Documentation Checklist for Appeal

A successful appeal typically includes:

• Most recent fasting lipid panel showing LDL-C above the guideline threshold
• Documentation of maximally tolerated statin therapy (name, dose, duration, any statin intolerance history with objective findings)
• ICD-10 codes for ASCVD (I25.10, I21.x) or HeFH (E78.01)
• Letter of medical necessity from the prescribing physician citing ACC/AHA 2022 guideline recommendations [5]
• Documentation of prior ezetimibe trial if the insurer requires it

Peer-to-peer review with the insurer's medical director, requested by the prescribing cardiologist, resolves roughly 40 to 60% of PCSK9 inhibitor denials in published plan audit data. [11]

External Appeal Rights

Under the Affordable Care Act, patients in non-grandfathered plans have the right to an independent external appeal when an internal appeal fails. The external appeal must be requested within the insurer's stated deadline (typically 60 days from denial). The Novartis One PSP team can help coordinate this process and supply supporting clinical literature.

Clinical Context: Who Needs Inclisiran Most

Inclisiran is approved for adults with primary hyperlipidemia or HeFH as an add-on to diet and maximally tolerated statin therapy. The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction identifies four major statin benefit groups and places PCSK9 inhibitors in the highest-risk tier, where LDL-C lowering beyond statins and ezetimibe is clinically justified. [5]

Heterozygous Familial Hypercholesterolemia

HeFH affects approximately 1 in 250 individuals worldwide, meaning roughly 1.3 million Americans carry the diagnosis. [12] Statins alone typically reduce LDL-C by 35 to 50%, but HeFH patients often start with LDL-C above 190 mg/dL, leaving them well above the 100 mg/dL target even on high-intensity therapy. Inclisiran provides an additional 50% reduction on top of statin therapy, making it one of the few options to reach goal in this population. [2]

Post-Acute Coronary Syndrome Patients

After an ACS event, the ACC/AHA guidelines recommend achieving LDL-C below 70 mg/dL, with an optional target of below 55 mg/dL for very-high-risk patients. [5] Many post-ACS patients cannot reach 70 mg/dL on statin alone, and a large subset is statin-intolerant. In the ORION-4 trial (N=7,011, ongoing), inclisiran is being tested as a secondary prevention agent in a MACE-outcomes design. Results from this trial will determine whether the LDL-C reductions translate to event reduction in a large RCT.

Statin Intolerance

Statin-associated muscle symptoms affect an estimated 5 to 10% of statin users in real-world registries, though blinded rechallenge trials suggest the true pharmacological rate is lower. [13] Because inclisiran acts entirely downstream through RNA interference and has no pharmacokinetic interaction with the mevalonate pathway, it does not cause myopathy. Patients with documented statin intolerance who need LDL-C reduction are strong candidates for inclisiran access program navigation.

Step-by-Step: Getting Leqvio at the Lowest Possible Cost

1. Confirm diagnosis and LDL-C threshold. The prescriber documents ASCVD or HeFH and confirms LDL-C is above the guideline-recommended threshold for PCSK9 escalation. [5]
2. Submit PA with complete documentation. Include statin trial history, current LDL-C, ICD-10 codes, and the ACC/AHA guideline citation. [5]
3. Enroll in Novartis One PSP simultaneously. Call 1-888-NOW-NOVA or go to leqvio.com to start a benefits investigation while the PA is pending. The PSP team will confirm co-pay card eligibility or route to NPAF if uninsured.
4. If denied, appeal immediately. Use the checklist above. Request peer-to-peer review. Exercise external appeal rights if needed under ACA provisions.
5. If on Medicare, explore Medigap and Extra Help. Medigap covers Part B coinsurance; Extra Help covers Part D cost-sharing for low-income beneficiaries. [8]
6. Use HSA/FSA for residual costs. Any remaining cost-sharing, administration fees, or office visit copays are IRS-qualified medical expenses. [9]
7. Confirm annual cap before dose 3 in year one. Three injections in year one may exhaust a program's annual cap sooner than expected.